Bio-Rad Q2 FY26 net income rises 16.9% to $371.4 million; net sales flat at $651 million
BIO•Q2 results
- Bio-Rad posted Q2 2026 GAAP net income of $371.4 million, up from $317.8 million, or $13.85 per diluted share.
- GAAP net sales were $651 million, essentially flat year over year; GAAP operating income slipped to $72.6 million from $77.1 million.
- GAAP gross margin edged up 0.1 percentage point to 53.1%, while operating cash flow fell to $98.7 million from $116.5 million.
Segment performance and outlook
- Life Science net sales fell 4.1% to $252 million, while Clinical Diagnostics rose 2.6% to $399 million.
- Bio-Rad reaffirmed its full-year outlook for non-GAAP, currency-neutral revenue of down about 3% to up about 0.5%.
